Home Biosimilar Antibodies Neuronal Signaling Others Latozinemab (Anti-Sortilin / SORT1)
For research use only. Not for use in humans.

Latozinemab (Anti-Sortilin / SORT1)

Synonyms: AL001

Latozinemab (anti-Sortilin / SORT1) is a recombinant humanized anti-Sortilin monoclonal antibody. Latozinemab has the potential for progranulin gene (GRN) mutations causative of frontotemporal dementia (FTD) (FTD-GRN) research. MW: 146.28 KD.

Latozinemab (Anti-Sortilin / SORT1)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 6.711mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Latozinemab (anti-Sortilin / SORT1) is a recombinant humanized anti-Sortilin monoclonal antibody. Latozinemab has the potential for progranulin gene (GRN) mutations causative of frontotemporal dementia (FTD) (FTD-GRN) research. MW: 146.28 KD.
References

Product Details

CAS No. 2376132-27-1
Molecular Weight 146.28
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06111014 TERMINATED Drug: Latozinemab Neurodegenerative Diseases Alector Inc. 2023-12-08 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-01-21)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.